Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial.
COVID-19
IL-6
IP-10
SARS-CoV-2
sarilumab
tocilizumab
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
03
11
2022
accepted:
10
03
2023
medline:
11
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels of interleukin (IL)-6 might benefit from blockade of the IL-6 pathway. However, the benefit from this intervention might not be uniform. In this subanalysis, we sought to determine if other immunoactivation markers, besides IL-6, could identify which subgroup of patients benefit most from this intervention. The SARICOR trial was a phase II, open-label, multicenter, controlled trial (July 2020-March 2021) in which patients were randomized to receive usual care (UC; control group), UC plus a single dose of sarilumab 200 mg (sarilumab-200 group), or UC plus a single dose of sarilumab 400 mg (sarilumab-400 group). Patients who had baseline serum samples for cytokine determination (IL-8, IL-10, monocyte chemoattractant protein-1, interferon-inducible protein [IP]-10) were included in this secondary analysis. Progression to acute respiratory distress syndrome (ARDS) according to cytokine levels and treatment received was evaluated. One hundred one (88%) of 115 patients enrolled in the SARICOR trial had serum samples (control group: n = 33; sarilumab-200: n = 33; sarilumab-400: n = 35). Among all evaluated biomarkers, IP-10 showed the strongest association with treatment outcome. Patients with IP-10 ≥2500 pg/mL treated with sarilumab-400 had a lower probability of progression (13%) compared with the control group (58%; hazard ratio, 0.19; 95% CI, 0.04-0.90; IP-10 may predict progression to ARDS in patients with COVID-19 pneumonia and IL-6 levels >40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels.
Sections du résumé
Background
UNASSIGNED
The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels of interleukin (IL)-6 might benefit from blockade of the IL-6 pathway. However, the benefit from this intervention might not be uniform. In this subanalysis, we sought to determine if other immunoactivation markers, besides IL-6, could identify which subgroup of patients benefit most from this intervention.
Methods
UNASSIGNED
The SARICOR trial was a phase II, open-label, multicenter, controlled trial (July 2020-March 2021) in which patients were randomized to receive usual care (UC; control group), UC plus a single dose of sarilumab 200 mg (sarilumab-200 group), or UC plus a single dose of sarilumab 400 mg (sarilumab-400 group). Patients who had baseline serum samples for cytokine determination (IL-8, IL-10, monocyte chemoattractant protein-1, interferon-inducible protein [IP]-10) were included in this secondary analysis. Progression to acute respiratory distress syndrome (ARDS) according to cytokine levels and treatment received was evaluated.
Results
UNASSIGNED
One hundred one (88%) of 115 patients enrolled in the SARICOR trial had serum samples (control group: n = 33; sarilumab-200: n = 33; sarilumab-400: n = 35). Among all evaluated biomarkers, IP-10 showed the strongest association with treatment outcome. Patients with IP-10 ≥2500 pg/mL treated with sarilumab-400 had a lower probability of progression (13%) compared with the control group (58%; hazard ratio, 0.19; 95% CI, 0.04-0.90;
Conclusions
UNASSIGNED
IP-10 may predict progression to ARDS in patients with COVID-19 pneumonia and IL-6 levels >40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels.
Identifiants
pubmed: 37035487
doi: 10.1093/ofid/ofad133
pii: ofad133
pmc: PMC10077828
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad133Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflict of interest. All authors report no potential conflicts.
Références
Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7
pubmed: 15657466
Front Immunol. 2021 Apr 26;12:668507
pubmed: 33981314
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0210721
pubmed: 34902262
Clin Microbiol Infect. 2023 Jan;29(1):7-9
pubmed: 36257548
BMJ Open. 2020 Nov 14;10(11):e039951
pubmed: 33191263
Sci Rep. 2015 Jun 01;5:10942
pubmed: 26028236
Int J Clin Pract. 2021 Sep;75(9):e14462
pubmed: 34107113
Autoimmun Rev. 2014 Mar;13(3):272-80
pubmed: 24189283
Natl Sci Rev. 2020 Jun;7(6):1003-1011
pubmed: 34676126
Sci Rep. 2022 Mar 28;12(1):5250
pubmed: 35347166
J Pers Med. 2021 Jul 20;11(7):
pubmed: 34357148
Front Immunol. 2021 Aug 20;12:681516
pubmed: 34489933
Am J Trop Med Hyg. 2020 Dec;103(6):2412-2418
pubmed: 33124544
Int J Clin Pract. 2021 Dec;75(12):e14970
pubmed: 34626520
JAMA. 2021 Aug 10;326(6):499-518
pubmed: 34228774
Cytokine. 2021 Jun;142:155500
pubmed: 33810947
Horm Metab Res. 2014 Aug;46(9):597-602
pubmed: 24977661
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Am J Respir Crit Care Med. 2021 Jan 15;203(2):192-201
pubmed: 33217246
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
JAMA Intern Med. 2021 Jan 1;181(1):24-31
pubmed: 33080005
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Nat Med. 2021 Oct;27(10):1752-1760
pubmed: 34480127
Cytokine. 2021 May;141:155428
pubmed: 33550165
J Transl Med. 2021 Jun 26;19(1):272
pubmed: 34174875
Sci Rep. 2020 Dec 10;10(1):21697
pubmed: 33303843
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
Clin Microbiol Infect. 2021 Feb;27(2):238-243
pubmed: 32979572